Tempus AI Inc. ( TEM )  reported second-quarter financial results Friday.

The AI-focused precision medicine and patient care company reported a second-quarter adjusted loss of 22 cents per share, beating analyst estimates for a loss of 24 cents per share.

Tempus AI ( TEM ) reported quarterly revenue of $314.64 million, beating the consensus estimates of $296.85 million. Revenue increased 89.6% year-over-year.

Genomics contributed $241.8 million in revenue in the quarter, growing 115.3% year over year.

Also Read:  Could Personalized Medicine Be Your Portfolio’s Next Big Winner? Find Out

Oncology testing (Tempus genomics) delivered $133.2 million of revenue, up 32.9%, with approximately 26% volume growth versus 20% last quarter.

Hereditary testing sales (Ambry genetics) reached $97.3 million, up 33.6% year-over-year on a pro forma basis with approximately 32% volume growth.

Revenue from Data and services totaled $72.8 million, delivering 35.7% growth versus the second quarter of 2024, led by Insights (data licensing), which grew 40.7% year-over-year.

Adjusted EBITDA of ($5.6 million) in the second quarter of 2025 compared to ($31.2 million) in the second quarter of 2024, an improvement of $25.6 million year-over-year.

“The business is performing well with revenues and margins growing faster than expected, contributing to our continued improvement in adjusted EBITDA on a year-over-year basis,” said Eric Lefkofsky, Founder and CEO of Tempus.

“We saw significant re-acceleration of our clinical volumes, which grew 30% in the quarter, as we delivered more than 212,000 NGS tests,” Lefkofsky said in a statement on Friday.

Database Update

Through more than 4,500 integrations, Tempus said it connected to more than 40 million clinical patient records, with around 9 million de-identified and ingested, spanning approximately 1.1 billion healthcare documents, a significant percentage of which are connected to the around 4 million samples the company has sequenced.

As a result, the company’s database stands at over 350 petabytes of connected clinical and molecular data.

Tempus AI ( TEM ) ended the quarter with $293.0 million in cash and marketable securities, an improvement of around $70 million over last quarter.

Outlook

Tempus AI ( TEM ) increased its guidance and expects a full year of 2025 revenue of approximately $1.26 billion for the consolidated business, representing approximately 82% annual growth, compared to the consensus of $1.25 billion.

Earlier, the company expected revenue between $1.24 billion and $1.25 billion for its consolidated Tempus and Ambry Genetics business.

The company reaffirms full-year 2025 adjusted EBITDA of $5 million, an improvement of approximately $110 million over 2024.

Tempus AI ( TEM ) received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its ejection fraction software in July.

Tempus said the FDA granted it 510(k) clearance for its Tempus ECG-Low EF software, which uses AI to identify patients with a potential left ventricular ejection fraction.

Price Action: Tempus AI ( TEM ) shares were up 5.79% after hours, trading at $55.21 at the time of publication on Tuesday.

Read Next:

Palantir, Nvidia & Tempus AI Could Be Pharma ETF Darlings That Don’t Make Pills